Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis

ANCA 类型和利妥昔单抗与环磷酰胺对 ANCA 相关性血管炎的心血管风险、死亡率和质量调整生命年的影响

基本信息

  • 批准号:
    10372989
  • 负责人:
  • 金额:
    $ 17.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-04-01 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

Candidate: Zachary S. Wallace, MD is an Instructor in Medicine at Harvard Medical School (HMS) and an Assistant in Medicine in the Rheumatology Unit at Massachusetts General Hospital (MGH). After his undergraduate degree in History from Cornell University, he received his MD at Georgetown University. He completed his medicine residency and rheumatology fellowship at MGH, during which Dr. Wallace began working with Hyon Choi, MD, DrPH. Dr. Wallace conducts patient-oriented research of multi-system rheumatic conditions, especially ANCA-associated vasculitis (AAV), which has resulted in 20 peer-reviewed original papers, with 10 as the first author and 6 in Arthr Rheum and Ann Rheum Dis. Dr. Wallace is completing his Master of Science in Epidemiology at Harvard University. His goal is to become an independent investigator and world-class leader in patient-oriented research of AAV and multi-system rheumatic conditions. Mentorship, Training Activities, and Environment: Dr. Wallace will conduct the proposed project at MGH under the mentorship of Hyon Choi, MD, DrPH and co-mentorship of John Stone, MD, MPH and Rochelle Walensky, MD, MPH. Dr. Choi is a world-renowned, NIH-funded physician scientist in advanced clinical epidemiology of rheumatic conditions, ranging from common disorders to rare but serious disorders (e.g., AAV). He has severed as a mentor for several prior K awardees. Dr. Stone is a clinical investigator and expert in AAV who has led landmark trials in AAV and other vasculitides. Dr. Walensky is an expert in decision science, simulation modeling, and cost-effectiveness analysis. Dr. Wallace' research will also benefit from the specific expertise of his key collaborators, including covariate definition algorithms, lipid analysis, quality of life measures, and external validation. To complement the expertise of his mentors, he will acquire new skills through didactics on advanced clinical epidemiology, pharmacoepidemiology, and simulation modeling. Research: Despite advances in AAV care, it continues to carry a 4-fold higher risk of cardiovascular disease (CVD), a 2-fold higher risk of death, and a significant quality-of-life impairment compared to the general population. The central goal of this research is to improve long-term AAV outcomes by determining the impact of key potential predictors such as ANCA types and initial treatment choice (rituximab (RTX) & cyclo- phosphamide (CYC)) on CVD risk, mortality, and quality-adjusted life years (QALYs). To achieve this goal, he will examine the impact of ANCA type and initial treatment choice on CVD and mortality in a large longitudinal AAV cohort using validated algorithms to assess covariates in electronic medical records (Aims 1& 2). He will also study the effect of RTX and CYC on lipid profiles using frozen samples from a randomized trial (Aim 2). Finally, he will project QALYs associated with initial induction therapy choice and ANCA type in a simulation model (Aim 3). Completion of this proposal and training plan will position Dr. Wallace with the vital experience to become an independent clinical investigator in patient-oriented research of AAV and similar conditions.
候选人:Zachary S. Wallace博士是哈佛医学院(HMS)的医学讲师, 马萨诸塞州总医院(MGH)流变学部门的医学助理。后 他在康奈尔大学获得历史学本科学位,在乔治敦大学获得医学博士学位。他 在MGH完成了他的医学住院医师和风湿病学奖学金,在此期间,华莱士博士开始 与Hyon Choi,MD,DrPH一起工作。华莱士博士进行以患者为导向的多系统风湿性关节炎研究 条件,特别是ANCA相关血管炎(AAV),这导致了20个同行评审的原始 论文,10作为第一作者,6在Arthr Rheum和Ann Rheum Dis。 哈佛大学流行病学硕士。他的目标是成为一名独立调查员 在以患者为导向的AAV和多系统风湿性疾病研究方面, 导师,培训活动和环境:华莱士博士将在MGH进行拟议的项目 在Hyon Choi,MD,DrPH和John Stone,MD,MPH和罗谢尔的共同指导下 Walensky,MD,MPH. Choi博士是一位世界知名的,NIH资助的高级临床医学科学家。 风湿性疾病的流行病学,范围从常见疾病到罕见但严重的疾病(例如, AAV)。他曾担任过几位K奖获得者的导师。斯通博士是一位临床研究者和专家 他领导了AAV和其他血管炎的里程碑式试验。瓦伦斯基博士是决策专家 科学、模拟建模和成本效益分析。华莱士博士的研究也将受益于 他的主要合作者的具体专业知识,包括协变量定义算法,血脂分析,生活质量 措施和外部验证。为了补充导师的专业知识,他将获得新的技能 通过先进的临床流行病学,药物流行病学和模拟建模教学。 研究:尽管AAV治疗取得了进展,但它仍然具有4倍的心血管疾病风险 (CVD),死亡风险高出2倍,与一般情况相比, 人口这项研究的中心目标是通过确定AAV对患者的影响, 关键的潜在预测因素,如ANCA类型和初始治疗选择(利妥昔单抗(RTX)和环, 环磷酰胺(CYC))对CVD风险、死亡率和质量调整生命年(QGR)的影响。为了实现这一目标,他 将在一个大的纵向研究中研究ANCA类型和初始治疗选择对CVD和死亡率的影响, 使用经验证的算法评估电子医疗记录中的协变量的AAV群组(目的1和2)。他将 还研究了RTX和CYC对血脂谱的影响,使用来自随机试验的冷冻样本(目的2)。 最后,他将在模拟中预测与初始诱导治疗选择和ANCA类型相关的Qs 模型(目标3)。完成本建议书和培训计划将使华莱士博士获得重要的经验 成为一名独立的临床研究者,从事以患者为导向的AAV和类似疾病的研究。

项目成果

期刊论文数量(35)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Multimodality Imaging Features of Immunoglobulin G4-related Vessel Involvement.
免疫球蛋白 G4 相关血管受累的多模态成像特征。
  • DOI:
    10.1148/ryct.230105
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    O'Shea,Aileen;Crotty,RoryK;Randhawa,MangunKaur;Oliveira,George;Perugino,CoryA;Stone,JohnH;Harisinghani,MukeshG;Wallace,ZacharyS;Hedgire,SandeepS
  • 通讯作者:
    Hedgire,SandeepS
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zachary Scott Wallace其他文献

Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
接种疫苗的系统性自身免疫性风湿病患者中 COVID-19 突破性感染的临床特征和结果
  • DOI:
    10.1136/annrheumdis-2021-221326
  • 发表时间:
    2022-02-01
  • 期刊:
  • 影响因子:
    20.600
  • 作者:
    Claire Cook;Naomi J Patel;Kristin M. D’Silva;Tiffany Y -T Hsu;Michael DiIorio;Lauren Prisco;Lily W Martin;Kathleen Vanni;Alessandra Zaccardelli;Derrick Todd;Jeffrey A Sparks;Zachary Scott Wallace
  • 通讯作者:
    Zachary Scott Wallace

Zachary Scott Wallace的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zachary Scott Wallace', 18)}}的其他基金

Personalizing AAV Management by Leveraging Big Data: Targeting Complication Clusters
利用大数据个性化 AAV 管理:针对并发症集群
  • 批准号:
    10369732
  • 财政年份:
    2021
  • 资助金额:
    $ 17.93万
  • 项目类别:
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis
ANCA 类型和利妥昔单抗与环磷酰胺对 ANCA 相关性血管炎的心血管风险、死亡率和质量调整生命年的影响
  • 批准号:
    10292270
  • 财政年份:
    2021
  • 资助金额:
    $ 17.93万
  • 项目类别:
Personalizing AAV Management by Leveraging Big Data: Targeting Complication Clusters
利用大数据个性化 AAV 管理:针对并发症集群
  • 批准号:
    10198103
  • 财政年份:
    2021
  • 资助金额:
    $ 17.93万
  • 项目类别:
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis
ANCA 类型和利妥昔单抗与环磷酰胺对 ANCA 相关性血管炎的心血管风险、死亡率和质量调整生命年的影响
  • 批准号:
    9886161
  • 财政年份:
    2018
  • 资助金额:
    $ 17.93万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 17.93万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.93万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 17.93万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.93万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 17.93万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.93万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 17.93万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 17.93万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 17.93万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.93万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了